SUBSCRIBE
SUBSCRIBE
News   Business

Zenyth And MuriGen Collaborate On Inflammation Targets

February 20, 2006 | 
1 min read

Zenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases. More...

Alliances Australia
MORE ON THIS TOPIC
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: Eli Lilly's biotechnology center in California
Manufacturing
Lilly Pumps $3B Into Wisconsin Site as Compounders Close In on Tirzepatide
December 6, 2024
 · 
2 min read
 · 
Tristan Manalac